MONECO Advisors LLC Acquires 346 Shares of GSK plc (NYSE:GSK)

MONECO Advisors LLC boosted its holdings in shares of GSK plc (NYSE:GSK) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,433 shares of the pharmaceutical company’s stock after purchasing an additional 346 shares during the period. MONECO Advisors LLC’s holdings in GSK were worth $461,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. FMR LLC lifted its position in shares of GSK by 7.7% during the 3rd quarter. FMR LLC now owns 18,099,513 shares of the pharmaceutical company’s stock worth $656,107,000 after buying an additional 1,291,161 shares during the period. Primecap Management Co. CA lifted its holdings in shares of GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 12,058,770 shares of the pharmaceutical company’s stock valued at $437,130,000 after acquiring an additional 287,000 shares during the period. Royal Bank of Canada lifted its holdings in shares of GSK by 5.1% during the third quarter. Royal Bank of Canada now owns 8,079,897 shares of the pharmaceutical company’s stock valued at $292,896,000 after acquiring an additional 389,871 shares during the period. Morgan Stanley boosted its stake in shares of GSK by 2.1% in the 3rd quarter. Morgan Stanley now owns 7,551,555 shares of the pharmaceutical company’s stock valued at $273,744,000 after purchasing an additional 156,480 shares in the last quarter. Finally, Provident Trust Co. grew its holdings in shares of GSK by 53.6% in the 4th quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock worth $137,746,000 after purchasing an additional 1,297,385 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

GSK has been the subject of several analyst reports. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Citigroup raised GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. Finally, Morgan Stanley assumed coverage on GSK in a report on Tuesday, January 23rd. They set an “equal weight” rating for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

GSK Stock Up 2.7 %

Shares of NYSE:GSK opened at $42.57 on Thursday. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 1.19. The firm has a market cap of $88.22 billion, a P/E ratio of 14.14, a P/E/G ratio of 1.46 and a beta of 0.65. GSK plc has a 12 month low of $33.33 and a 12 month high of $43.84. The company’s 50-day moving average price is $41.82 and its two-hundred day moving average price is $39.06.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.04). The company had revenue of $10 billion for the quarter, compared to the consensus estimate of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. As a group, research analysts forecast that GSK plc will post 4.03 EPS for the current fiscal year.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.